Cervical Cancer
Pegylated liposomal doxorubicin has limited activity as second-line chemotherapy
Published in Clinical Trials Week, September 25th, 2006
"Doxorubicin has reported activity in advanced and recurrent cervical cancer but hematologic toxicity has limited its use in some combinations. To determine the level of activity and potential for use in future combinations, a phase II trial of pegylated liposomal doxorubicin as second-line therapy in advanced and recurrent cervical cancer was performed," scientists writing in the journal Gynecologic Oncology report.
"Eligible patients had squamous cell carcinoma of the cervix, measurable disease, one prior...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
Source: Clinical Trials Week (2006-09-25)
More Articles from Clinical Trials Week
- Alzheimer Disease
Accera initiates phase II trial for age associated memory impairment therapy - Clinical Trials
Atrial fibrillation incidence in chronic heart failure patients is reduced with candesartan - Clinical Trials
Starpharma initiates U.S. NIH-funded trial of microbicide for sexually transmitted diseases - Leukemia
Childhood T-lineage acute lymphoblastic leukemia associated with high expression of Delta TA-p73 - Urology
Oxybutynin appears well tolerated compared to tolterodine for overactive bladder - Alzheimer Disease
Memantine is safe and effective treatment for mild to moderate Alzheimer disease - More from this issue of Clinical Trials Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
